20/20 Biolabs Inc (NASDAQ:AIDX) Short Interest Update

20/20 Biolabs Inc (NASDAQ:AIDX) was the recipient of a large growth in short interest during the month of May. As of May 29th, there was short interest totaling 128,775 shares, a growth of 613.4% from the May 14th total of 18,050 shares. Approximately 1.2% of the shares of the company are sold short. Based on an average daily trading volume, of 1,125,074 shares, the days-to-cover ratio is presently 0.1 days.

20/20 Biolabs Trading Down 6.0%

20/20 Biolabs stock opened at $0.79 on Wednesday. 20/20 Biolabs has a 1-year low of $0.78 and a 1-year high of $50.00. The company has a 50 day simple moving average of $1.44.

20/20 Biolabs (NASDAQ:AIDX) last posted its quarterly earnings results on Wednesday, May 20th. The company reported ($0.28) earnings per share for the quarter. The company had revenue of $0.35 million during the quarter.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on AIDX shares. Wall Street Zen upgraded 20/20 Biolabs to a “hold” rating in a research note on Saturday, March 14th. Maxim Group started coverage on 20/20 Biolabs in a research note on Monday, May 11th. They issued a “buy” rating and a $5.00 target price on the stock. Finally, Weiss Ratings started coverage on 20/20 Biolabs in a research note on Thursday, May 14th. They issued a “sell (e-)” rating on the stock. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, 20/20 Biolabs has a consensus rating of “Hold” and a consensus target price of $5.00.

20/20 Biolabs Company Profile

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.